Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open label, randomized phase II trial for patients with previously
untreated metastatic or locally advanced esophagogastric cancer, using a pick the winner
design to identify the best combination therapy in terms of progression free survival and
neurotoxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)